Visual Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) commonly co-exists with type 2 diabetes. Alanine aminotransferase (ALT) levels are known to correlate, to some degree, with liver inflammation.

Methods: All data submitted to the ABCD nationwide empagliflozin audit programme were included if they had relevant baseline and follow-up data and were then stratified by baseline ALT for two analyses: 1) using gender-specific reference ranges; 2) by normal (<30U/L), mildly raised (30-59 U/L) and very raised levels (twice male reference limit, ≥60 U/L). Data were analysed using non-parametric methods due to skew using Stata SE 16.

Results: 6510 datasets were included with mean(±SD) age 60.0yrs(±10.4), 61.2% male, BMI 34.2kg/m2(±6.5), HbA1c 9.3%(±1.6) and weight 98.4kg(±21.23). For the entire population, median ALT changed by -4 U/L (95% CI -4, -4; P<0.01). When stratified, in both analyses, all groups showed significant changes in ALT from baseline. These are shown in Figure 1.

Conclusion: Our data demonstrate changes in ALT associated with empagliflozin use. Decreases of a significantly greater magnitude are noted in those with raised ALT at baseline. Empaglifozin may provide benefit in NAFLD.

graphic
View largeDownload slide
Disclosure

T. S. J. Crabtree: Other Relationship; Self; Novo Nordisk, Sanofi. J. Elliott: Advisory Panel; Self; Abbott, Speaker’s Bureau; Self; Abbott, Dexcom, Inc., Insulet Corporation, Novo Nordisk. A. Bickerton: None. I. W. Gallen: None. K. Dhatariya: Speaker’s Bureau; Self; Novo Nordisk. M. L. Cull: None. A. Evans: None. S. M. Phillips: None. R. E. Ryder: Other Relationship; Self; Novo Nordisk.

Funding

Boehringer Ingelheim

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.